NICE Recommends TheraSphere as Treatment for HCC

The National Institute for Health and Care Excellence has issued guidance recommending the use of TheraSphere Y-90 Glass Microspheres, from Boston Scientific, as a treatment for patients with hepatocellular carcinoma (HCC).

According to a Feb 26, 2021 press release from Boston Scientific, based on the results of more than 100 clinical studies, the effectiveness of TheraSphere to improve tumor response in all stages of liver cancer has been proven. The targeted treatment, which is commonly known as selective internal radiation therapy (SIRT), can be used as an outpatient procedure.

“Outpatient treatment options are important for patients diagnosed with liver cancer as they are especially vulnerable to complications from COVID-19 and the use of TheraSphere can help avoid risk of exposure to infection in the healthcare setting,” said Jane Healy, vice-president Peripheral Interventions, EMEA at Boston Scientific, in the press release. “We look forward to bringing this proven treatment option to a greater number of patients with HCC, to improve their chance of survival against this disease in today’s challenging healthcare landscape and for many years to come.”